Sandoz Q1 Sales $2.492B Up From $2.384B YoY
Portfolio Pulse from Benzinga Newsdesk
Sandoz reported a strong first quarter with sales reaching $2.492B, a 5% increase in USD and 6% in constant currencies compared to last year. The biosimilar business grew by 21% in constant currencies. Growth was seen across all regions. Additionally, the acquisition of CIMERLI (ranibizumab-eqrn) was completed in March 2024.
May 07, 2024 | 7:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sandoz's Q1 report shows a positive trend with sales increasing to $2.492B, a 5% rise YoY, and significant growth in the biosimilar sector. The completion of the CIMERLI acquisition could further bolster its portfolio.
The reported increase in sales and the significant growth in the biosimilar business indicate a strong performance by Sandoz. The acquisition of CIMERLI is likely to enhance its product portfolio and contribute to future growth, positively impacting investor sentiment and potentially the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100